Journal of Biological Chemistry · 1995 · 66 citations · 48 references
Life SciencesBiochemistryMolecular BiologyCell SignalingProtein-protein InteractionsSignal TransductionCell-surface ReceptorsGrowth Factor SignalingLigand BindingProtein Interaction DomainsProtein StructureSmall Gtpase SignalingInsulin Receptor SignalingInsulin ReceptorsInsulin-like Growth Factor Receptor SignalingInsulin-like Growth Factor-1Insulin-like Growth FactorsSh2 Domain-mediated SignalingSh2 DomainsSh2-binding Motif
Potential signaling substrates for the insulin-like growth factor I (IGF-I) receptor are SH2 domain proteins including the p85 subunit of phosphatidylinositol 3-kinase, the tyrosine phosphatase Syp, GTPase activating protein (GAP), and phospholipase C-γ (PLC-γ). In this study, we demonstrate an association between the IGF-I receptor and p85, Syp, and GAP, but not with PLC-γ in lysates of cells overexpressing the human IGF-I receptor. We further investigated these interactions using glutathione S-transferase (GST) fusion proteins containing the amino-terminal SH2 domains of p85 or GAP, or both SH2 domains of Syp or PLC-γ to precipitate the IGF-I receptor from purified receptor preparations and from whole cell lysates. p85-, Syp-, and GAP-GSTs precipitated the IGF-I receptor, whereas the PLC-γ-GST did not. Using phosphopeptides corresponding to IGF-I receptor phosphorylation sites, we determined that the p85- and Syp-GST association with the IGF-I receptor could be inhibited by a carboxyl-terminal peptide containing pY1316 and that the GAP-GST association could be inhibited by a NPXY domain peptide. The GAP-GST binding site was confirmed by showing that a mutant IGF-I receptor with a deletion of the NPXY domain including tyrosine 950 was poorly precipitated by the GAP-GST. We conclude that p85 and Syp may bind directly to the IGF-I receptor at tyrosine 1316, and that GAP may bind to the IGF-I receptor at tyrosine 950. An association between the IGF-I receptor and PLC-γ was not evident. p85, Syp, and GAP are potential modulators of IGF-I receptor signal transduction. Potential signaling substrates for the insulin-like growth factor I (IGF-I) receptor are SH2 domain proteins including the p85 subunit of phosphatidylinositol 3-kinase, the tyrosine phosphatase Syp, GTPase activating protein (GAP), and phospholipase C-γ (PLC-γ). In this study, we demonstrate an association between the IGF-I receptor and p85, Syp, and GAP, but not with PLC-γ in lysates of cells overexpressing the human IGF-I receptor. We further investigated these interactions using glutathione S-transferase (GST) fusion proteins containing the amino-terminal SH2 domains of p85 or GAP, or both SH2 domains of Syp or PLC-γ to precipitate the IGF-I receptor from purified receptor preparations and from whole cell lysates. p85-, Syp-, and GAP-GSTs precipitated the IGF-I receptor, whereas the PLC-γ-GST did not. Using phosphopeptides corresponding to IGF-I receptor phosphorylation sites, we determined that the p85- and Syp-GST association with the IGF-I receptor could be inhibited by a carboxyl-terminal peptide containing pY1316 and that the GAP-GST association could be inhibited by a NPXY domain peptide. The GAP-GST binding site was confirmed by showing that a mutant IGF-I receptor with a deletion of the NPXY domain including tyrosine 950 was poorly precipitated by the GAP-GST. We conclude that p85 and Syp may bind directly to the IGF-I receptor at tyrosine 1316, and that GAP may bind to the IGF-I receptor at tyrosine 950. An association between the IGF-I receptor and PLC-γ was not evident. p85, Syp, and GAP are potential modulators of IGF-I receptor signal transduction. The insulin-like growth factor I (IGF-I) 1The abbreviations used are: IGFinsulin-like growth factorPLCphospholipase CGAPGTPase activating proteinGSTglutathione S-transferaseIRSinsulin receptor substratePIphosphatidylinositolPAGEpolyacrylamide gel electrophoresisPAOphenylarsine oxide. 1The abbreviations used are: IGFinsulin-like growth factorPLCphospholipase CGAPGTPase activating proteinGSTglutathione S-transferaseIRSinsulin receptor substratePIphosphatidylinositolPAGEpolyacrylamide gel electrophoresisPAOphenylarsine oxide. receptor is a member of the large family of tyrosine kinase growth factor receptors which undergo autophosphorylation upon ligand binding(1Hanks S.K. Quinn A.M. Hunter T. Science. 1988; 241: 42-52Crossref PubMed Scopus (3804) Google Scholar, 2Ullrich A. Schlessinger J. Cell. 1990; 61: 203-212Abstract Full Text PDF PubMed Scopus (4605) Google Scholar). The activated receptor is then able to transduce this signal intracellularly by interacting with specific downstream protein substrates, ultimately resulting in hormonal effects such as cellular growth and differentiation(3Hunter T. Cooper J.A. Annu. Rev. Biochem. 1985; 54: 897-930Crossref PubMed Google Scholar, 4Yarden Y. Ullrich A. Annu. Rev. Biochem. 1988; 57: 443-478Crossref PubMed Scopus (1390) Google Scholar). Autophosphorylation of the IGF-I receptor is followed immediately by phosphorylation of insulin receptor substrate-1 (IRS-1)(5White M.F. Maron R. Kahn C.R. Nature. 1985; 318: 183-186Crossref PubMed Scopus (450) Google Scholar, 6White M.F. Stegmann E.W. Dull T.J. Ullrich A. Kahn C.R. J. Biol. Chem. 1987; 262: 9769-9777Abstract Full Text PDF PubMed Google Scholar, 7Izumi T. White M.F. Kadowaki T. Takaku F. Akanuma Y. Kasuga M. J. Biol. Chem. 1987; 262: 1282-1287Abstract Full Text PDF PubMed Google Scholar, 8Myers M.G. Sun X.J. Cheatham B. Jachna B.R. Glasheen E.M. Backer J.M. White M.F. Endocrinology. 1993; 132: 1421-1430Crossref PubMed Scopus (227) Google Scholar). insulin-like growth factor phospholipase C GTPase activating protein glutathione S-transferase insulin receptor substrate phosphatidylinositol polyacrylamide gel electrophoresis phenylarsine oxide. insulin-like growth factor phospholipase C GTPase activating protein glutathione S-transferase insulin receptor substrate phosphatidylinositol polyacrylamide gel electrophoresis phenylarsine oxide. The tyrosine phosphorylation of IRS-1 transforms this 185-kDa molecule into a “docking” protein, facilitating its interaction with a number of other signaling molecules containing Src homology 2 (SH2) domains(9Sun X.J. Rothenberg P Kahn C.R. Backer J.M. Araki E. Wilden P.A. Cahill D.A. Goldstein B.J. White M.F. Nature. 1991; 352: 73-77Crossref PubMed Scopus (1284) Google Scholar, 10White M.F. Kahn C.R. J. Biol. Chem. 1994; 269: 1-4Abstract Full Text PDF PubMed Google Scholar). SH2 domains are conserved regions of ~100 amino acids that promote association with phosphorylated tyrosines surrounded by specific amino acid motifs such as those found in IRS-1 and activated growth factor receptors(11Koch C.A. Anderson D. Moran M.F. Ellis C. Pawson T. Science. 1991; 252: 668-674Crossref PubMed Scopus (1437) Google Scholar, 12Songyang Z. Shoelson S.E. Chaudhuri M Gish G. Pawson T. Haser W.G. King F. Roberts T. Ratnofsky S. Lechleider R.J. Neel B.G. Birge R.B. Fajardo J.E. Chou M.M. Hanafusa H. Schaffhausen B. Cantley L.C. Cell. 1993; 72: 767-778Abstract Full Text PDF PubMed Scopus (2381) Google Scholar). Although IRS-1 is clearly an important signaling molecule for the insulin and IGF-I receptors (5White M.F. Maron R. Kahn C.R. Nature. 1985; 318: 183-186Crossref PubMed Scopus (450) Google Scholar, 6White M.F. Stegmann E.W. Dull T.J. Ullrich A. Kahn C.R. J. Biol. Chem. 1987; 262: 9769-9777Abstract Full Text PDF PubMed Google Scholar, 7Izumi T. White M.F. Kadowaki T. Takaku F. Akanuma Y. Kasuga M. J. Biol. Chem. 1987; 262: 1282-1287Abstract Full Text PDF PubMed Google Scholar, 8Myers M.G. Sun X.J. Cheatham B. Jachna B.R. Glasheen E.M. Backer J.M. White M.F. Endocrinology. 1993; 132: 1421-1430Crossref PubMed Scopus (227) Google Scholar, 13Rose D.W. Saltiel A.R. Majumdar M. Decker S.J. Olefsky J.M. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 797-801Crossref PubMed Scopus (124) Google Scholar, 14Sun X.J. Miralpeix M. Myers M.G. Glasheen E.M. Backer J.M. Kahn C.R. White M.F. J. Biol. Chem. 1992; 267: 22662-22672Abstract Full Text PDF PubMed Google Scholar), recent evidence gained from IRS-1 knockout mice has suggested that an alternative signaling pathway(s) exists(15Tamemoto H. Kadowaki T. Tobe K. Yagi T. Sakura H. Hayakawa T. Terauchi Y. Ueki K. Kaburagi Y. Satoh S. Sekihara H. Yoshioka S. Horikoshi H. Faruta Y. Ikawa Y. Kasuga M. Yazaki Y. Aizawa S. Nature. 1994; 372: 182-186Crossref PubMed Scopus (904) Google Scholar, 16Araki E. Lipes M.A. Patti M.-E. Bruning J.C. Haag B. Johnson R.S. Kahn C.R. Nature. 1994; 372: 186-190Crossref PubMed Scopus (1093) Google Scholar). We hypothesize that one such pathway may result from the direct association of potential signaling molecules with the IGF-I receptor. Recently, Van Horn et al.(17Van Horn D.J. Myers Jr., M.G. Backer J.M. J. Biol. Chem. 1994; 269: 29-32Abstract Full Text PDF PubMed Google Scholar), demonstrated that the p85 subunit of phosphatidylinositol 3-kinase (PI 3-kinase) interacts directly with the insulin receptor, and we have localized this insulin receptor binding site to the YXXM motif at tyrosine 1322 (18Staubs P.A. Reichart D.R. Saltiel A.R. Milarski K.L. Maegawa H. Berhanu P. Olefsky J.M. Seely B.L. J. Biol. Chem. 1994; 269: 27186-27192Abstract Full Text PDF PubMed Google Scholar). Although direct association of p85 with the IGF-I receptor has not previously been demonstrated, PI 3-kinase activity increases after IGF-I stimulation. Furthermore, Yamamoto et K. D. E. K. S. J. Biol. Chem. 1992; 267: Full Text PDF PubMed Google that PI 3-kinase activity with IGF-I receptors and be with of a p85 fusion Syp is a protein tyrosine phosphatase that SH2 Syp is the of an SH2 phosphatase in to signal of the receptor tyrosine kinase Pawson T. Science. 1993; PubMed Scopus Google Scholar, Jr., J. Neel B.G. Proc. Natl. Acad. Sci. U. S. A. 1992; PubMed Scopus Google Scholar, R. J. Ullrich A. Science. 1993; PubMed Scopus Google Scholar, Cell. 1992; Full Text PDF PubMed Scopus Google Scholar). that Syp is in signal of receptor as of Syp to a in and S. D.W. T. Maegawa H. Shoelson S.E. Olefsky J.M. J. Biol. Chem. 1994; 269: Full Text PDF PubMed Google Scholar, K.L. Saltiel A.R. J. Biol. Chem. 1994; 269: Full Text PDF PubMed Google Scholar). Syp is to bind to X.J. Myers Jr., M.G. Miralpeix M. White M.F. Cell. Biol. 1993; PubMed Google Scholar), but we and have demonstrated that a S-transferase (GST) fusion protein directly with the insulin receptor at tyrosine P.A. Reichart D.R. Saltiel A.R. Milarski K.L. Maegawa H. Berhanu P. Olefsky J.M. Seely B.L. J. Biol. Chem. 1994; 269: 27186-27192Abstract Full Text PDF PubMed Google Scholar, H. S. M. Y. R. A. Y. A. Biochem. 1994; Scopus Google Scholar). directly with the growth factor S. Lechleider R.J. Shoelson S.E. Neel B.G. J. Biol. Chem. 1993; Full Text PDF PubMed Google and growth factor A. Pawson T. M. Proc. Natl. Acad. Sci. U. S. A. 1993; PubMed Scopus Google is not Syp directly with the IGF-I receptor. protein is SH2 domain protein in tyrosine kinase growth factor receptor signal transduction. GAP by the of as a of signal P. F. J. Biol. Chem. 1992; Full Text PDF Google Scholar). GAP directly with the activated insulin receptor R. F. J. Biol. Chem. 1992; 267: Full Text PDF PubMed Google at tyrosine P.A. Reichart D.R. Saltiel A.R. Milarski K.L. Maegawa H. Berhanu P. Olefsky J.M. Seely B.L. J. Biol. Chem. 1994; 269: 27186-27192Abstract Full Text PDF PubMed Google Scholar), but is not GAP interacts with the IGF-I receptor. C-γ is SH2 domain protein which is directly to the activated and growth factor receptors and is an important signaling J. Hunter T. Cell. 57: Full Text PDF PubMed Scopus Google Scholar). association between PLC-γ and the insulin or IGF-I receptors has been In this study, we the direct association of p85, Syp, GAP, and PLC-γ with the IGF-I receptor and the of receptor interaction SH2 fusion proteins and phosphopeptides after domains of the IGF-I receptor. cells as D. A. Olefsky J.M. Endocrinology. 1994; PubMed Scopus Google with the containing the human IGF-I receptor previously by Ullrich et A. A. T. M. C. T. S. E. S. U. J. Y. J. PubMed Scopus Google Scholar). The cells with and a receptors was used in these cell overexpressing the human IGF-I receptor with a deletion of the NPXY domain was used in D. A. Olefsky J.M. Endocrinology. 1994; PubMed Scopus Google Scholar). cells in from with and and by and from The and from the receptor was from and the was from The and the from was from and was from the and from and the was from from and after the amino acid of specific IGF-I receptor tyrosine phosphorylation the tyrosine kinase domain the NPXY domain and and the carboxyl-terminal The are: and The peptide was not used of this peptide in the peptide which we The of the SH2 domain proteins used in this is G. Decker S.J. Saltiel A.R. Proc. Natl. Acad. Sci. U. S. A. 1992; PubMed Scopus Google Scholar). The p85 fusion protein used to from p85, including the amino-terminal SH2 The Syp-GST to of Syp, including both SH2 The GAP-GST amino acids to of GAP, including the amino-terminal SH2 and the PLC-γ-GST to of including the and carboxyl-terminal SH2 The and of fusion proteins has been P.A. Reichart D.R. Saltiel A.R. Milarski K.L. Maegawa H. Berhanu P. Olefsky J.M. Seely B.L. J. Biol. Chem. 1994; 269: 27186-27192Abstract Full Text PDF PubMed Google Scholar, Johnson 1988; PubMed Scopus Google Scholar). IGF-I receptors purified from cells by and binding as D.A. Maegawa H. J. Dull T.J. A. Olefsky J.M. J. Biol. Chem. 1987; 262: Full Text PDF PubMed Google Scholar). of purified IGF-I receptors with of kinase at 2 and IGF-I for at of an activating in kinase was then at and the was to for was with of 2 and at of a of in of the fusion proteins phosphopeptides at this The for at the and the was with The in 2 and by gel to with a using the whole cell lysates used of purified in whole cell with for at with phenylarsine was by the cells with for at with IGF-I for at the and of was of the cell was then with the fusion protein of and as The IGF-I receptor was from whole cell lysates with a receptor at a of an the was with IRS-1 was with a M. Decker S.J. Saltiel A.R. J. Biol. Chem. 1992; 267: Full Text PDF PubMed Google at a of and was precipitated with after an at The was using an at a of the and at and at was with the at a of a at with the proteins which are in in to IGF-I stimulation. in cells are at and the 185-kDa as IRS-1 and the as the IGF-I receptor Although GAP was in the whole cell lysates by an GAP was not in using an 2 and after GAP was not in the GAP in the whole cell lysates but is not the protein at protein is both in the and in the and its is not 2 to demonstrate an interaction between the IGF-I receptor and signaling molecules in whole cell lysates. In whole cell of with IGF-I for at then precipitated with an receptor and with was with a a an or a PLC-γ The of p85 be in the Syp protein be in and GAP was precipitated by the IGF-I receptor the whole cell with phenylarsine oxide. The of this protein tyrosine phosphatase was suggested by the insulin receptor previously by et R. F. J. Biol. Chem. 1992; 267: Full Text PDF PubMed Google Scholar). PLC-γ was not in the IGF-I receptor that p85, Syp, and GAP, but not are precipitated with the IGF-I receptor. is not these proteins are directly with the IGF-I receptor or with other proteins which with the IGF-I receptor such as further the of direct IGF-I domain protein we the of SH2 fusion proteins to directly with the IGF-I receptor. of fusion proteins containing the amino-terminal SH2 domain of p85, both SH2 domains of Syp, the amino-terminal SH2 domain of GAP, or both SH2 domains of PLC-γ with whole cell lysates and In of receptor precipitated in the of the The was able to precipitate and the IGF-I receptor from whole cell lysates the Syp-GST was used in of p85 The of the precipitated by the p85- and the Syp-GST is was precipitated by the Syp-GST from cells with and overexpressing the human insulin receptor and a mutant Syp by a to K.L. Saltiel A.R. J. Biol. Chem. 1994; 269: Full Text PDF PubMed Google Scholar). IRS-1 was precipitated by both the p85- and the Syp-GST at a was the IGF-I receptor, that these fusion proteins may have a for IRS-1 for the IGF-I receptor. The IGF-I receptor was not precipitated by the GAP-GST or by the PLC-γ-GST C and phosphorylated proteins precipitated by the PLC-γ-GST but the GAP-GST was able to precipitate a an and a from whole cell lysates. protein be in the of the and the PLC-γ-GST is the of the fusion may the tyrosine phosphorylation of the fusion proteins or binding by the used in the using purified receptors from preparations not to IRS-1 is a in the association of the IGF-I receptor with the p85- and and clearly that the p85- and the are both able to precipitate the IGF-I receptor in the of that p85 and Syp directly with the IGF-I receptor. In to the from the cell the GAP-GST precipitated the IGF-I receptor from the purified receptor preparations The PLC-γ-GST did not precipitate this fusion protein precipitate activated growth factor and the growth factor receptor M. Decker S.J. Saltiel A.R. J. Biol. Chem. 1992; 267: Full Text PDF PubMed Google Scholar). was of that the GAP-GST did not precipitate IGF-I receptors from whole cell but did precipitate purified IGF-I We cell with a phosphatase to and IGF-I in an to IGF-I receptor phosphorylation to potential interactions between the GAP-GST and the IGF-I receptor in cell lysates. these the IGF-I receptor is precipitated by the GAP-GST. is a in the at and and The of these proteins are not are precipitated by the PLC-γ-GST with and of the in the phosphorylated protein at was from tyrosine phosphorylation of GAP, whole cell of with then with the and with an that GAP is not in whole cell lysates. after tyrosine phosphorylation of GAP be clearly and In after of IGF-I in the of of the cellular GAP protein is precipitated by the 2 and GAP in whole cells with The a direct association between p85, Syp, and GAP fusion proteins and the IGF-I receptor. We a of to the specific SH2 domain binding the receptor. We this by the of to with the IGF-I receptor for binding to fusion The phosphopeptides after regions of the IGF-I receptor with important autophosphorylation the tyrosine of the kinase H. B. Roberts D. 1994; PubMed Scopus Google Scholar), the NPXY D. A. Olefsky J.M. Endocrinology. 1994; PubMed Scopus Google Scholar), and the carboxyl-terminal including tyrosine H. B. D. Roberts J. Biol. Chem. 1994; 269: Full Text PDF PubMed Google Scholar). The tyrosine peptide is after amino acids to in the IGF-I receptor tyrosine kinase domain and the tyrosines important in receptor The NPXY peptide was after amino acids to from the IGF-I this did not a the peptide was used in its pY1316 is from the of the IGF-I receptor and amino acids to that binding to the IGF-I receptor is inhibited by of the receptor is precipitated by the in the of pY1316 In the tyrosine peptide the NPXY peptide was able to the receptor interaction at a of to with the Syp fusion IGF-I receptor was inhibited in a by pY1316 with at a of In to of the tyrosine or of the peptide did not IGF-I receptor by the that both p85 and Syp with the phosphorylated IGF-I receptor at tyrosine that the receptor interaction be inhibited by of the In was with the tyrosine or the carboxyl-terminal phosphopeptides this a cell overexpressing mutant IGF-I receptors with deletion of the NPXY motif to was D. A. Olefsky J.M. Endocrinology. 1994; PubMed Scopus Google Scholar). and that this mutant receptor is precipitated by the at both and In mutant receptor is precipitated at a of the and a of receptor is precipitated at GAP-GST. in the p85 and GAP-GST proteins are in to precipitate the IGF-I receptor. IRS-1 is to be important in insulin and IGF-I receptor signal transduction. recent in IRS-1 knockout mice has suggested the of signaling H. Kadowaki T. Tobe K. Yagi T. Sakura H. Hayakawa T. Terauchi Y. Ueki K. Kaburagi Y. Satoh S. Sekihara H. Yoshioka S. Horikoshi H. Faruta Y. Ikawa Y. Kasuga M. Yazaki Y. Aizawa S. Nature. 1994; 372: 182-186Crossref PubMed Scopus (904) Google Scholar, 16Araki E. Lipes M.A. Patti M.-E. Bruning J.C. Haag B. Johnson R.S. Kahn C.R. Nature. 1994; 372: 186-190Crossref PubMed Scopus (1093) Google Scholar). In this we evidence to a direct interaction between p85, Syp, and GAP and the IGF-I receptor. We have localized the of SH2 domain binding to the IGF-I receptor phosphopeptides from important autophosphorylation the IGF-I receptor. receptor was able to precipitate p85 from whole cell lysates from a of Although be in these this a direct and interaction between p85 and the IGF-I receptor, an interaction between p85 and IRS-1 in a IGF-I Although the of the IGF-I interaction is poorly is IRS-1 not with the IGF-I receptor an IGF-I receptor is E. P. Chaudhuri M. Backer J.M. Kahn C.R. White M.F. 1992; Scopus Google Scholar), the IGF-I receptor with IRS-1 an IRS-1 is M.G. Sun X.J. Cheatham B. Jachna B.R. Glasheen E.M. Backer J.M. White M.F. Endocrinology. 1993; 132: 1421-1430Crossref PubMed Scopus (227) Google Scholar). The to IGF-I in this but not that the of p85 in the receptor precipitate from an IGF-I We these to a direct interaction between p85 and the IGF-I receptor. Backer et J.M. Myers M.G. Sun X.J. D.J. Shoelson S.E. Miralpeix M. White M.F. J. Biol. Chem. 1993; Full Text PDF PubMed Google have previously that p85 could with IRS-1 or directly with the insulin receptor, as as of the cellular p85 in was with IRS-1 in cells that the interaction is the by which PI 3-kinase is activated upon insulin M.G. Sun X.J. Cheatham B. Jachna B.R. Glasheen E.M. Backer J.M. White M.F. Endocrinology. 1993; 132: 1421-1430Crossref PubMed Scopus (227) Google Scholar, X.J. Rothenberg P Kahn C.R. Backer J.M. Araki E. Wilden P.A. Cahill D.A. Goldstein B.J. White M.F. Nature. 1991; 352: 73-77Crossref PubMed Scopus (1284) Google Scholar, E. P. Chaudhuri M. Backer J.M. Kahn C.R. White M.F. 1992; Scopus Google Scholar, J.M. Myers M.G. Sun X.J. D.J. Shoelson S.E. Miralpeix M. White M.F. J. Biol. Chem. 1993; Full Text PDF PubMed Google Scholar, X.J. Miralpeix M. Myers Jr., M.G. Glasheen E.M. Backer J.M. Kahn C.R. White M.F. J. Biol. Chem. 1992; 267: 22662-22672Abstract Full Text PDF PubMed Google Scholar, J.M. Myers Jr., M.G. Shoelson S.E. D.J. Sun Miralpeix M. P. B. Schlessinger J. White M.F. J. 1992; PubMed Scopus Google Scholar). mice with a knockout of the IRS-1 are not to signal to PI 3-kinase including a direct H. Kadowaki T. Tobe K. Yagi T. Sakura H. Hayakawa T. Terauchi Y. Ueki K. Kaburagi Y. Satoh S. Sekihara H. Yoshioka S. Horikoshi H. Faruta Y. Ikawa Y. Kasuga M. Yazaki Y. Aizawa S. Nature. 1994; 372: 182-186Crossref PubMed Scopus (904) Google Scholar, 16Araki E. Lipes M.A. Patti M.-E. Bruning J.C. Haag B. Johnson R.S. Kahn C.R. Nature. 1994; 372: 186-190Crossref PubMed Scopus (1093) Google Scholar). The interaction of the IGF-I receptor with p85 directly or IRS-1 has been suggested PI 3-kinase activity with IGF-I receptors and be with of a p85 fusion K. D. E. K. S. J. Biol. Chem. 1992; 267: Full Text PDF PubMed Google Scholar). The activated IGF-I receptor is to protein in with those phosphorylated by the insulin receptor, including those in the motif to bind M.G. Sun X.J. Cheatham B. Jachna B.R. Glasheen E.M. Backer J.M. White M.F. Endocrinology. 1993; 132: 1421-1430Crossref PubMed Scopus (227) Google Scholar, X.J. Rothenberg P Kahn C.R. Backer J.M. Araki E. Wilden P.A. Cahill D.A. Goldstein B.J. White M.F. Nature. 1991; 352: 73-77Crossref PubMed Scopus (1284) Google Scholar, X.J. Myers Jr., M.G. Miralpeix M. White M.F. Cell. Biol. 1993; PubMed Google Scholar, S. R. A. S. Van E. J. Biol. Chem. 1993; Full Text PDF PubMed Google Scholar, S.E. S. Chaudhuri M. White M.F. Proc. Natl. Acad. Sci. U. S. A. 1992; PubMed Scopus Google Scholar, L.C. C. B. A. R. S. Cell. 1991; Full Text PDF PubMed Scopus Google Scholar). The binding for the SH2 domains of p85 is and the in the is for p85 SH2 X.J. Myers Jr., M.G. Miralpeix M. White M.F. Cell. Biol. 1993; PubMed Google Scholar, J.M. Myers Jr., M.G. Shoelson S.E. D.J. Sun Miralpeix M. P. B. Schlessinger J. White M.F. J. 1992; PubMed Scopus Google Scholar). We have previously that the containing the amino-terminal SH2 domain of p85 bind to the of the insulin receptor at the binding motif P.A. Reichart D.R. Saltiel A.R. Milarski K.L. Maegawa H. Berhanu P. Olefsky J.M. Seely B.L. J. Biol. Chem. 1994; 269: 27186-27192Abstract Full Text PDF PubMed Google Scholar). In this we the direct binding of the to the IGF-I receptor and a binding site to a binding in the We the that IGF-I receptor other those we may in p85 Although IRS-1 and the IGF-I receptor both with p85 after IGF-I the of interaction to signaling Syp is an tyrosine phosphatase which to in a X.J. Myers Jr., M.G. Miralpeix M. White M.F. Cell. Biol. 1993; PubMed Google Scholar, H. S. M. Y. R. A. Y. A. Biochem. 1994; Scopus Google Scholar, T. Schlessinger J. Biol. 1993; Full Text PDF PubMed Scopus Google Scholar, R. M. Schaffhausen Backer J. White M.F. Cantley L.C. 1991; PubMed Scopus Google Scholar, D. S. B. Schlessinger J. Shoelson S.E. J. 1994; Full Text Full Text PDF PubMed Scopus Google Scholar). We that an receptor precipitate for p85, we this a direct receptor interaction an IGF-I interaction of the of the IGF-I Furthermore, we have in that a Syp-GST may bind directly to the IGF-I receptor at in a binding We have not the that other receptor not may be in Syp binding as the of amino-terminal SH2 domain of Syp in with demonstrate the of a in the D. S. B. Schlessinger J. Shoelson S.E. J. 1994; Full Text Full Text PDF PubMed Scopus Google Scholar). The IGF-I receptor has a amino in the from tyrosine The of the receptor the interaction has not been but have Syp as a of and S. D.W. T. Maegawa H. Shoelson S.E. Olefsky J.M. J. Biol. Chem. 1994; 269: Full Text PDF PubMed Google Scholar, K.L. Saltiel A.R. J. Biol. Chem. 1994; 269: Full Text PDF PubMed Google Scholar). GAP is to with IGF-I receptors precipitated from whole cell lysates from of with phenylarsine oxide. GAP-GST with purified IGF-I receptors in and with IGF-I receptors from whole cell lysates with phenylarsine oxide. Using we have determined that the SH2 domain of the GAP-GST interacts with the IGF-I receptor at tyrosine 950. The motif of a with a amino acid in the and and is with GAP binding previously for the growth factor S. Lechleider R.J. Shoelson S.E. Neel B.G. J. Biol. Chem. 1993; Full Text PDF PubMed Google Scholar, J.A. A. Cell. Biol. 1993; PubMed Scopus Google and the insulin P.A. Reichart D.R. Saltiel A.R. Milarski K.L. Maegawa H. Berhanu P. Olefsky J.M. Seely B.L. J. Biol. Chem. 1994; 269: 27186-27192Abstract Full Text PDF PubMed Google Scholar). is that GAP could be precipitated with the IGF-I receptor from cells with phenylarsine oxide. for this result is that the of phosphorylation after with this protein tyrosine phosphatase is in its receptors in a for to a receptors in whole M.F. S. Kahn C.R. J. Biol. Chem. 1985; Full Text PDF PubMed Google Scholar, A.R. J. J. Biol. Chem. 1988; Full Text PDF PubMed Google Scholar, J.M. Biochem. J. 1988; 252: PubMed Scopus Google Scholar). We we able to the tyrosine phosphorylation of the IGF-I receptors in whole cells by with a phosphatase of the IGF-I et R. F. J. Biol. Chem. 1992; 267: Full Text PDF PubMed Google found an association between the insulin receptor and GAP in whole cell lysates after with with the association of GAP and the IGF-I receptor, we have found that IGF-I to tyrosine phosphorylation of GAP GAP tyrosine phosphorylation was in the of the phosphatase In the this tyrosine phosphorylation may be of further that GAP may with the IGF-I receptor in and may be a of the IGF-I receptor signaling interaction may be by The IGF-I receptor not with in the of or the PLC-γ-GST is used at In this we that the IGF-I receptor may directly with SH2 domain proteins including p85, Syp, and We have the IGF-I receptor binding site for p85 and Syp to tyrosine in the and the binding site for GAP to tyrosine 950 in the NPXY The association between these proteins and the IGF-I receptor may an to directly these signaling
48
SH2 domains recognize specific phosphopeptide sequences
Cell · 1993 · 2.7K citations
A. Ullrich, Andrew Gray, Albert W. Tam et al. · The EMBO Journal · 1986 · 1.9K citations · Full text
Morris F. White, C. Ronald Kahn · Journal of Biological Chemistry · 1994 · 1.7K citations · Full text